Marker Therapeutics Inc (MRKR)

[Inoviorulez]

Biggest improvement for MultiTAA is epitope spread. The ability to get other T-cells (immune system) to create their own antigen targets on tumor cells.

This kind of happened as an accident. At baylor their goal was to use 5 antigens for one tumor, because they know tumors adapt and change (become heterogenous). That's why CAR-T and TCR therapies, which target one antigen, don't have durable responses out to 30 + months. Their target is one antigen which is CD19 and if the cancer tumor doesn't portray that all around its surface, then the therapy dies off. On the other hand, when MultiTAA was given to patients they have durable responses because not only does the 5 antigens take care of the heterogenous nature of the tumor, but it recruits the remaining parts of the immune system in a "hey look at that tumor over there create your own antigens and attack it" and that's what they saw in their studies.